Stock Scorer

Prime Medicine, Inc. (PRME) · Insider trading

What Prime Medicine's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.

Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$0
0 insiders
Net, 12 months
$0
bought less sold
Latest filing
2025-08-05
filings read to 2026-10-19

Bought and sold at the market, by month

Two years. Purchases above the line, sales below, in dollars.

2025-01 2025-05: $284,300 bought 2025-06: $163,170 bought 2025-07 2025-08: $34.95M bought 2026-01 2026-07
Bought Sold Largest month: $34.95M

Who traded, two years

InsiderBoughtSold TradesLast tradeHolds after
Crandell Keith10% owner $10.00M – 1 2025-08-01 –
Arch Venture Fund Xii, L.P.10% owner $10.00M – 1 2025-08-01 –
Nelsen RobertDirector, 10% owner $10.00M – 1 2025-08-01 –
Alphabet Inc.10% owner $4.95M – 1 2025-08-01 –
Liu David R.10% owner $163,170 – 4 2025-06-30 20,240,945
Reine AllanDirector, Chief Executive Officer $147,500 – 1 2025-05-21 125,000
Lee Ann L.Chief Technical Officer $113,000 – 1 2025-05-21 100,000
Brudnick RichardChief Business Officer $23,800 – 1 2025-05-20 20,000

Open-market purchases and sales

Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.

DateInsiderTradeShares PriceValueHolds afterFiling
2025-08-01 Alphabet Inc.10% ownerwith Gv 2021, L.P., Gv 2021 GP, L.L.C., Gv 2021 GP, L.P. Buyindirect 1,500,000 3.30 $4.95M 3,262,440 Form 4
2025-08-01 Crandell Keith10% ownerwith Gillis Steven, Burow Kristina, Arch Venture Fund X, L.P., Arch Venture Fund X Overage, L.P., Arch Venture Partners X Overage, L.P., Arch Venture Partners X, LLC, Arch Venture Partners X, L.P. Buyindirect 3,030,300 3.30 $10.00M 6,230,300 Form 4
2025-08-01 Arch Venture Fund Xii, L.P.10% ownerwith Arch Venture Partners Xii, LLC, Arch Venture Partners Xii, L.P. Buyindirect 3,030,300 3.30 $10.00M 6,230,300 Form 4
2025-08-01 Nelsen RobertDirector, 10% owner Buyindirect 3,030,300 3.30 $10.00M 6,230,300 Form 4
2025-06-30 Liu David R.10% owner Buyplan 21,000 2.52 $52,920 20,240,945 Form 4
2025-06-23 Liu David R.10% owner Buyplan 21,000 2.16 $45,360 20,219,945 Form 4
2025-06-16 Liu David R.10% owner Buyplan 21,000 1.49 $31,290 20,198,945 Form 4
2025-06-11 Liu David R.10% owner Buyplan 21,000 1.60 $33,600 20,177,945 Form 4
2025-05-21 Reine AllanDirector, Chief Executive Officer Buy 125,000 1.18 $147,500 125,000 Form 4
2025-05-21 Lee Ann L.Chief Technical Officer Buy 100,000 1.13 $113,000 100,000 Form 4
2025-05-20 Brudnick RichardChief Business Officer Buy 20,000 1.19 $23,800 20,000 Form 4

How to read it

Buy, sale
Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
Plan
A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
Holds after
The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
Value
Shares times the price the form reports, which is often an average over several fills on the day.

Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.

Prime Medicine's scores and multiples ›